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SummaRy Neurofibromatosis 1 (NF-1) is an autosomal dominant 
genodermatosis with an increased risk of developing mesenchymal 
malignancies. 
A 28-year-old woman with NF-1 was admitted to our Department for 
deep ulcers on the right thigh. The ulcerations had appeared about 
two years earlier, and were initially diagnosed as pyoderma gangreno-
sum. The patient received immunosuppressive therapy but only mar-
ginal improvement was observed. Several months later, the disease 
progressed, so a skin biopsy was taken, establishing cytophagic his-
tiocytic panniculitis. The patient was admitted to our Department for 
further therapy. After re-evaluation of histological slides, while taking 
into account the clinical presentation and previously established his-
tological diagnosis, subcutaneous panniculitis-like T cell lymphoma 
(SPTL) was diagnosed. Chemotherapy (combination of fludarabine 
and cyclophosphamide) was started, resulting in almost complete re-
mission of malignant lesions.
To the best of our knowledge, this is the first report of the develop-
ment of SPTL in NF-1.
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INTRoduCTIoN
Neurofibromatosis type 1 (NF-1, Recklinghausen’s 
disease – OMIM 162200) is an autosomal dominant 
inherited genodermatosis caused by mutations in 
the NF-1 gene on chromosome 17q11.2 that encodes 
neurofibromin (1). According to the National Insti-
tutes of Health (2), NF-1 is diagnosed based on clini-
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cal presentation if the patient fulfils at least two of the 
following seven criteria: presenting with six or more 
café au lait spots (with a diameter of >0.5 cm in chil-
dren or >1.5 cm in adults), axillary or groin freckling, 
two or more Lisch nodules, two or more neurofibro-
mas or one plexiform neurofibroma, optic pathway 
glioma, bone dysplasia, and having a first-degree 
family relative with NF-1. Patients with NF-1 may also 
demonstrate a broad spectrum of other clinical fea-
tures, including learning problems, renal artery ste-
nosis, arterial hypertension, pruritus, and many oth-
ers. In addition, they show increased risk of develop-
ing some malignancies, mainly malignant peripheral 
nerve sheath tumors or leukemia (1,3). In this paper, 
we report on a patient with NF-1 with a subcutane-
ous panniculitis-like T-cell lymphoma (SPTL). To the 
best of our knowledge, this is the first description of 
the coexistence of this unique and rare lymphoma 
with NF-1.
CaSe RePoRT
A 28-year-old woman with NF-1, diagnosed based 
on numerous café-au-lait macules, multiple neurofi-
bromas, Lisch nodules, and positive family history of 
NF-1 (the patient’s father and brother were diagnosed 
with NF-1), was admitted to our Department because 
of deep ulcers on the right thigh (Figure 1A). The first 
ulcerations had appeared about two years prior to 
admission, and were initially diagnosed as pyoderma 
gangrenosum based on clinical presentation. At that 
time, the patient received immunosuppressive ther-
apy (alternating systemic corticosteroids, cyclospo-
rine A, and sulphasalazine), which at first resulted in a 
partial healing of the ulcers. However, several months 
later, the disease begun to progress despite continu-
ous immunosuppression, so a skin biopsy was taken 
from the edge of one ulcer. The histology revealed 
cytophagic histiocytic panniculitis. The patient was 
transferred to our Department for further diagnostics 
and therapy. 
On admission, two deep ulcers covered with ne-
crotic tissue were noted (Figure 1A), in addition to the 
typical features of NF-1. The patient also complained 
of severe pain, preventing her from sleeping and re-
quiring a combined analgesic therapy (combination 
of buprenorphine 1.6 mg/day, ketoprofen 100 mg/
day, and carbamazepine 400 mg/day). Taking into 
account the clinical presentation and previously es-
tablished histological diagnosis, after re-evaluation 
of previous histological slides and new skin biopsy, 
the diagnosis of SPTL was finally established (Figures 
2 and 3). Laboratory examinations revealed a slightly 
elevated erythrocyte sedimentation rate (30 mm/h), 
an increased level of C-reactive protein (11.2 mg/L, 
normal value <7.0 mg/L) and fibrinogen (5.71 g/L, 
normal value 2.0-4.5 g/L), low serum iron (6.7 µmol/L, 
normal value 8.9-30.3 µmol/L), and decreased immu-
noglobulin G (IgG) serum level (6.96 g/L, normal val-
ue 8.0-17.0 g/L). Other routine laboratory tests, also 
including blood smear, were within the normal range 
or negative. Sonography of the abdomen revealed 
hepato- (16.8 cm) and splenomegaly (13.2×6.3 cm). 
Lymph nodes were not enlarged (both clinically and 
according to the sonography test). Trepanobiopsy did 
not reveal any malignant cells infiltrating the bone 
marrow. In addition, no clinical symptoms of hemo-
phagocytic syndrome were observed.  
Chemotherapy (FC – a combination of fludarabine 
25 mg/m2 and cyclophosphamide 250 mg/m2 on days 
1-3, 28-day cycles) was started, resulting in partial re-
mission after two cycles. Patient completed 6 FC cy-
Figure 1
A) Two deep ulcers covered with necrotic tissue on the right thigh. 
B) Current status of the patient with almost completely healed lesions.
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cles with almost complete remission being achieved. 
Then, due to disease progression, two cycles of gem-
citabine – GVP (1 g/m2, days 1 and 8), vinorelbine (30 
mg/m2, days 1 and 8), and prednisone (100 mg/day, 
days 1–8) were administered, but due to significant 
prolonged myelotoxicity (grade 4 neutropenia and 
thrombocytopenia) this regimen was stopped. Cur-
Figure 2
An overview of tumor histology (H&E, original mag-
nification: x40).
A) Histological features of panniculitis (H&E, original 
magnification: x100)
B) Larger magnification of histological slide with 
atypical large lymphocytes and hemophagocytosis 
(arrowhead) (original magnification: x200)
C) Positive staining for CD3 (original magnification: 
x400)
D) Positive staining for CD8 (original magnification: 
x400)
E) Negative staining for CD30 (original magnification: 
x200)
F) Negative staining for CD56 (original magnification: 
x200)
G) Positive staining for CD68 (original magnification: 
x400)
H) Positive staining for TIA-1 (original magnification: 
x400)
I) Negative staining for granzyme B (original magni-
fication: x400)
rently the patient remains under observation, receiv-
ing only wound dressings. For the last 8 months, slow 
wound healing has been noted, without any symp-
toms of tumor progression (Figure 1B). Topically gell-
ing foam dressing (Versiva® XC™) was applied during 
the entire treatment period. 
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dISCuSSIoN
SPTL, first described in 1991 by Gonzales et al. 
(4), is a rare lymphoma showing features imitating 
panniculitis, and is frequently associated with he-
mophagocytic syndrome (5). According to European 
Organization for Research and Treatment of Cancer 
– World Health Organization (EORTC-WHO) classifica-
tion, only SPTL showing α/β T-cell phenotype (SPTL-
AB) is nowadays considered true SPTL, while SPTL 
showing γ/δ T-cell phenotype (SPTL-GD) belongs to 
the provisional group of cutaneous γ/δ T-cell lym-
phomas (5). The most typical clinical presentations 
of SPTL-AB are nodular skin lesions or deeply seated 
plaques, whereas ulcers are less commonly observed. 
About 20% of patients with SPTL-AB have concomi-
tant autoimmune disorder (5). To the best of our 
knowledge, this is the first description of a patient 
with NF-1 developing SPTL. However, patients with 
NF-1 were reported to have developed many other 
lymphomas and hematologic malignancies (6-9). 
The long-term course of the disease strongly sug-
gests that our patient suffers from SPTL-AB, as SPTL-GD 
usually presents with more aggressive behavior and a 
much poorer outcome of treatment. STPL can also be 
easily misdiagnosed, both clinically and histologically, as 
benign panniculitis, including lupus panniculitis, which 
may delay correct diagnosis for a long time. SPTL-AB 
sometimes responds to immunosuppressive treatment 
with prednisone and cyclosporine, particularly during 
the initial phase of the disease (10,11), as also observed 
in our patient. However, not all patients achieve remis-
sion on immunosuppression, the response is usually 
short, and the disease progresses over time (12). Re-
garding other therapies, the CHOP regimen is the most 
popular one (5,12,13). However, we used another treat-
ment scheme for our patient, namely a combination 
of fludarabine and cyclophosphamide. That treatment 
modality was used with success by our group in the past 
to treat another case of primary cutaneous T-cell lym-
phoma (14). Interestingly, other authors also reported 
promising results of fludarabine-based regimens in pa-
tients with SPTL lymphoma(15-18). However, this was 
the first time our combination of chemotherapeutics 
(FC) was used to treat SPTL. 
CoNSLuSIoN
Our case report provides new data on SPTL, since, 
to the best of our knowledge, this is the first case of 
SPTL in a patient with NF-1. Furthermore, an almost 
complete remission was achieved using a combination 
of fludarabine and cyclophosphamide, a treatment 
regimen that was used for the first time for this type of 
lymphoma. 
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